Mortality from any cause (15‐day and 30‐day in‐hospital) · DIC
1 finding from 1 review
Adverse events · DIC
1 finding from 1 review
Bleeding · DIC
It is very uncertain whether dermatan changes bleeding compared with heparin (very low certainty).
1 finding from 1 review
Resolution of respiratory failure · DIC
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Renal failure · DIC
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Shock · DIC
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse events · DIC
It is very uncertain whether human activated protein C changes adverse events compared with heparin (very low certainty).
1 finding from 1 review
Bleeding · DIC
It is very uncertain whether human activated protein C changes bleeding compared with heparin (very low certainty).
1 finding from 1 review
Resolution of respiratory failure · DIC
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Renal failure · DIC
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Shock · DIC
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Overall mortality · DIC
1 finding from 1 review
Mortality from any cause (15‐day and 30‐day in‐hospital) · DIC
It is very uncertain whether recombinant human soluble thrombomodulin changes mortality from any cause (15‐day and 30‐day in‐hospital) compared with heparin (very low certainty).
1 finding from 1 review
Intervention not reported
Arterial thrombotic events (6 to 48 hours after CC) · children with congenital heart disease undergoing CC
The intervention showed no clear difference in arterial thrombotic events (6 to 48 hours after CC) (moderate certainty).
1 finding from 1 review
Intervention not reported
Major bleeding events (timing not specified) · children with congenital heart disease undergoing CC
The intervention showed no clear difference in major bleeding events (timing not specified) (moderate certainty).
1 finding from 1 review
Intervention not reported
Minor bleeding events (timing not specified) · children with congenital heart disease undergoing CC
The intervention showed no clear difference in minor bleeding events (timing not specified) (moderate certainty).
1 finding from 1 review
Intervention not reported
Other thrombotic events: venous thrombosis (up to 48 hours after CC) · children with congenital heart disease undergoing CC
The intervention showed no clear difference in other thrombotic events: venous thrombosis (up to 48 hours after CC) (moderate certainty).
1 finding from 1 review
Live birth · women with persistent antiphospholipid antibodies and recurrent pregnancy loss
It is very uncertain whether aspirin changes live birth compared with placebo (very low certainty).
1 finding from 1 review
Pre‐eclampsia · women with persistent antiphospholipid antibodies and recurrent pregnancy loss
It is very uncertain whether aspirin changes pre‐eclampsia compared with placebo (very low certainty).
1 finding from 1 review
Adverse events in the mother ‐ Bleeding · women with persistent antiphospholipid antibodies and recurrent pregnancy loss
It is very uncertain whether aspirin changes adverse events in the mother ‐ Bleeding compared with placebo (very low certainty).
1 finding from 1 review